ID   DUTKO-1
AC   CVCL_6217
SY   DUTKO1; DUTKO
DR   Wikidata; Q54831595
RX   PubMed=3930277;
RX   PubMed=6278187;
RX   PubMed=6278188;
CC   Selected for resistance to: ChEBI; CHEBI:472805; Ouabain.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_ZI16 ! DUT
HI   CVCL_0004 ! K-562
CA   Hybrid cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 8
//
RX   PubMed=3930277;
RA   Garson D., Dokhelar M.-C., Wakasugi H., Mishal Z., Tursz T.;
RT   "HLA class-I and class-II antigen expression by human leukemic K562
RT   cells and by Burkitt-K562 hybrids: modulation by differentiation
RT   inducers and interferon.";
RL   Exp. Hematol. 13:885-890(1985).
//
RX   PubMed=6278187; DOI=10.1093/jnci/68.2.179;
RA   Zeuthen J., Klein G., Ber R., Masucci G., Bisballe S., Povey S.,
RA   Terasaki P.I., Ralph P.;
RT   "Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. I.
RT   Isolation, characterization, cell surface markers, and B-cell
RT   markers.";
RL   J. Natl. Cancer Inst. 68:179-195(1982).
//
RX   PubMed=6278188; DOI=10.1093/jnci/68.2.197;
RA   Klein G., Zeuthen J., Ber R., Ernberg I.;
RT   "Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II.
RT   Epstein-Barr virus induction patterns.";
RL   J. Natl. Cancer Inst. 68:197-202(1982).
//